Loading...
•
Dec 31, 2021
Eagle Q4 2021 Earnings Report
Reported a net loss and an adjusted non-GAAP net income for Q4 2021.
Key Takeaways
Eagle Pharmaceuticals reported Q4 2021 financial results with a net loss of $(0.48) per share and adjusted non-GAAP net income of $0.85 per diluted share. The company launched two new products, vasopressin and PEMFEXY, and anticipates a strong Q1 2022.
Q4 2021 net loss was $(0.48) per basic and diluted share.
Adjusted non-GAAP net income was $0.87 per basic and $0.85 per diluted share.
Started shipping vasopressin with 180 days of marketing exclusivity.
Launched PEMFEXY, a branded alternative to ALIMTA.
Revenue by Segment
Forward Guidance
The company anticipates Q1 2022 revenue to be in the range of $120 million - $130 million and adjusted non-GAAP earnings per share in the range of $3.80 - $4.10.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...